We're a team
with
a shared
goal:
improve
patient
outcomes.
At Tempus, we are on a mission to
redefine how genomic data is
used in a
clinical setting. Our goal is for each
patient to benefit from
the treatment of
others who came before by providing
physicians
with tools that learn as we
gather more data.
Our leadership
team.
Eric Lefkofsky
Co-Founder and CEO
Eric Lefkofsky is the co-founder and CEO at Tempus. He is a founding partner of Lightbank, a venture fund investing in disruptive technology businesses. He is also the co-founder and Chairman of Groupon (NASDAQ: GRPN), a global e-commerce marketplace, and co-founder of Uptake Technologies, a leading predictive analytics platform for the world’s largest industries; Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; and InnerWorkings (NASDAQ: INWK), a global provider of managed print and promotional solutions. He co-chairs the Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. Lefkofsky serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry and World Business Chicago. He is also Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. Lefkofsky is an adjunct professor at the University of Chicago and author of Accelerated Disruption: Understanding the True Speed of Innovation. He graduated from the University of Michigan and received his Juris Doctor at University of Michigan Law School. For more information, visit lefkofsky.com, connect on LinkedIn and follow him on Twitter (@lefkofsky) and Facebook (@eplefkofsky).
Read more
Kevin White, PhD
President
Dr. Kevin White serves as President at Tempus, where he oversees the scientific operation. Dr. White was the founding Director of the Institute for Genomics and Systems Biology at The University of Chicago, where he retains an appointment as the James and Karen Frank Family Professor of Human Genetics and Medicine. Dr. White is a pioneer in combining experimental and computational techniques to understand the networks of factors that control biological systems during development, disease, and evolution. His team has discovered novel cancer genes in a wide range of tumor types including breast cancer, kidney cancer and myeloid leukemias. From 2006 through 2016, while he was the Founding Director of the Institute for Genomics & Systems Biology, Dr. White built a team of 10 faculty and over 100 staff that has won approximately $150M in research funding contracts and awards. His academic awards for innovation include the Keck Biomedical Investigator and Beckman Young Investigator awards, and he has also been recognized for his entrepreneurship on the ‘40 under 40’ list by Chicago Crain’s Business. White has served on the scientific boards of a wide range of start-up biotech companies and foundations. He also has previously served as acting CEO and co-director of HealthSeq Pvt. Ltd., providing hospitals with protected data clouds for analysis of genome and clinical records data. In the nonprofit sector he currently holds scientific advisory board positions at institutions that include Harvard University, Yale University, Northwestern University and the National Cancer Institute. Dr. White has a B.S. and M.S. from Yale and a Ph.D. from Stanford University.
Read more
Gary Palmer, MD
Chief Medical Officer
Dr. Gary Palmer serves as Chief Medical Officer at Tempus, where he is responsible for leading clinical activities for the company and supporting external collaborations and strategic partnerships. Dr. Palmer most recently served as the Chief Medical Officer for NantHealth. Prior to his time there he served as Senior Vice President, Medical Affairs and Commercial Development at Foundation Medicine, where he helped launch the FoundationOne assay. Earlier in his career, Dr. Palmer served as the Chief of Medical Oncology at Mercy Health System, Sacramento and head of their Oncology Service Line. Prior to that he was as an Associate Professor of Medicine at University of California Davis Cancer Center. He earned a bachelor’s degree from Yale University, his medical degree from Stanford University School of Medicine and his masters of public health from the UCLA Fielding School of Public Health.
Read more
Nike Beaubier, MD
Director of Pathology and Medical Lab Operations
Dr. Nike Beaubier serves as Director of Pathology and Medical Lab Operations at Tempus. Dr. Beaubier most recently served as Medical Director of the Diagnostic Molecular Biology Laboratory at Northwestern Memorial Hospital and Assistant Professor of Pathology at Northwestern University Feinberg School of Medicine. She earned a bachelor’s degree in molecular biology from the University of Texas, Austin, a master of science from Stanford University and her medical degree from Columbia University. She completed an Anatomic Pathology residency, followed by a Molecular Genetic Pathology Fellowship at Columbia, then a Gastrointestinal/Surgical Pathology Fellowship at Northwestern University.
Read more
Erik Phelps
Executive Vice President and General Counsel
Erik Phelps serves as Executive Vice President and General Counsel at Tempus, where he is responsible for a broad range of legal areas for the company, including general corporate matters and strategy. Phelps most recently served as General Counsel at Epic, a software company that provides electronic health records for medical groups, hospitals and healthcare organizations. Prior to his time there, he served as a partner at Michael Best & Friedrich LLP in Madison, WI where he focused on software licensing and technology related work, including work with early-stage companies. He earned a bachelor’s degree from Beloit College and his J.D. from George Washington University Law School.
Read more
Shane Colley
Senior Vice President of Engineering
Shane Colley is the Senior Vice President of Engineering at Tempus. Prior to joining Tempus, Colley was Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he built and led a global organization of over 200 product, architecture, design, and development professionals that were responsible for R1's technology portfolio. Colley earned his Bachelor of Science in Computer Science from Iowa State University.
Read more
Ryan Fukushima
Chief Operating Officer
Ryan Fukushima serves as Chief Operating Officer at Tempus. Prior to Tempus, Fukushima was an Entrepreneur-in-Residence and Vice President at Lightbank, focusing investments on enterprise software and launching businesses. Earlier he was at Hyde Park Venture Partners, where he concentrated on enterprise investments in the Midwest. Before landing in Chicago, Fukushima worked predominantly as an engineer, designing and implementing backend systems for Cisco and VMware. Fukushima has received a bachelor’s degree in Engineering from California Polytechnic University and holds an MBA from the Ross School of Business at University of Michigan, where he was a Zell Scholar.
Read more
David Agus, MD
Chairman of the Scientific Advisory Board
Dr. David Agus is Chairman of the Scientific Advisory Board at Tempus. He is a professor of medicine and engineering at the University of Southern California, where he leads USC’s Lawrence J. Ellison Institute for Transformative Medicine. He specializes in treating patients with advanced cancer. At USC, his clinical responsibilities include the development of clinical trials for new drugs and treatments for cancer, supported by the National Cancer Institute and other private foundations. He earned a bachelor’s degree from Princeton University, his medical degree from University of Pennsylvania’s School of Medicine and participated in a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center.
Read more
Arul Chinnaiyan,
MD, PhD
Scientific Adviser
Dr. Arul M. Chinnaiyan serves as Scientific Adviser at Tempus. He is an Investigator of the Howard Hughes Medical Institute, American Cancer Society Research Professor, and S.P. Hicks Endowed Professor of Pathology and Urology at the University of Michigan. He also serves as the inaugural Director of the Michigan Center for Translational Pathology (MCTP) which is comprised of a multi-disciplinary team of investigators focused on translating “-Omic” technologies to patient care in terms of biomarkers and novel therapeutics. He has co-authored over 400 manuscripts and has been designated an A. Alfred Taubman Medical Research Institute Scholar and is an elected member of the American Academy of Arts and Sciences (AAAS), the National Academy of Medicine (NAM), the Association of American Physicians (AAP) and the American Society for Clinical Investigation (ASCI). He serves on the Board of Scientific Advisors for the National Cancer Institute. Dr. Chinnaiyan, who received his medical degree and doctorate in pathology from the U-M, has received a number of prestigious awards, including the Dean’s Basic Science Research Award, the Amgen Outstanding Investigator Award, and the Pew Biomedical Scholar Award. In 2008 he received the American Association of Cancer Research (AACR) Award for Outstanding Achievement in Cancer Research. In 2007 Dr. Chinnaiyan and his team were the recipients of the inaugural AACR Team Science Award. He has received a number of other prestigious awards including the 2009 Paul Marks Prize for Cancer Research, 2009 Philip Levine Award for Cancer Research, 2007 Ramzi Cotran Award from the United States and Canadian Academy of Pathology, 2005 Benjamin Castleman Award, and the 2005 Amgen Outstanding Investigator by the American Society of Investigative Pathology. Most recently, in 2013, he received the Distinguished University Innovator Award from the University of Michigan as well as the Urology Care Foundation’s Prostate Cancer Excellence Award.
Read more
Dr. Andrea Califano
Scientific Adviser
Dr. Andrea Califano, serves as Scientific Adviser at Tempus. He is the Clyde and Helen Wu Professor of Chemical Systems Biology at Columbia University Medical Center. He is the Founding Chair of the Department of Systems Biology, Director of the JP Sulzberger Columbia Genome Center, and Associate Director for Bioinformatics of the Herbert Irving Comprehensive Cancer Center, and also holds appointments in the Department of Biochemistry & Molecular Biophysics and Department of Biomedical Informatics. Califano also co-founded DarwinHealth, a precision focused cancer medicine company that uses RNA analysis in an effort to match patients with treatment.

Prior to joining Columbia University in 2003, Dr. Califano worked at the IBM TJ Watson Research Center, where he became program director of the IBM Computational Biology Center. In 2000 he co-founded First Genetic Trust, Inc. to pursue translational genomics research. Dr. Califano serves on numerous editorial and scientific advisory boards, including the MIT Koch Cancer Center, MIT Physical Sciences in Oncology Center, Khalifa Institute of Personalized Medicine at MD Anderson Cancer Center, Gustave Roussy Cancer Center, Pershing Square Foundation, Cancer Genetics Inc and DawrinHealth Inc. Califano completed his doctoral thesis in physics at the University of Florence, Italy.
Read more
Kimberly Yeatts
Senior Director of Clinical Lab Operations
Kimberly Yeatts serves as the Senior Director of Clinical Lab Operations at Tempus. Prior to joining Tempus, Yeatts worked as the Director of Molecular Assay Development at Med Fusion. Earlier, she worked at Caris Life Sciences where she served in a number of different roles and was responsible for everything from next generation sequencing assay development to molecular diagnostic lab management to emerging technology scientific assessments. Yeatts earned her Bachelor of Science in Biology from Arizona State University and completed post baccalaureate training at the National Institutes of Health.
Read more
The Tempus
Lab.
We've built a state-of-the-art lab to bring
data science and technology into clinical
care. The CLIA-certified Tempus Lab is a
highly robotic
laboratory optimized for
high-throughput clinical next-generation
sequencing with a current capacity of
over 50,000 patients annually.
All sequencing includes RNA-seq
capture and germline. Sequencing is
completed within ~two weeks to three weeks of
receiving patient samples.
Download our CLIA certificate
Download our CAP certificate